<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392623</url>
  </required_header>
  <id_info>
    <org_study_id>71-15</org_study_id>
    <nct_id>NCT03392623</nct_id>
  </id_info>
  <brief_title>DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.</brief_title>
  <official_title>DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de San Luis Potosí</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de San Luis Potosí</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Malar melasma has a chronic and recurrent character that may be related with
      epigenetic changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE: Recognize the DNA methylation status of the malar melasma and perilesional skin,
      and its change after treatment with 50 SPF sunscreen (S), 4% niacinamide (N), or 0.025%
      retinoic acid (RA). METHODS: Fifty-six lesion of 28 female patients without treatment were
      clinically evaluated, as also the expression of DNA methyl transferases 1 and 3 by real
      time-PCR (polymerase chain reaction amplification), immunohistochemistry and
      immunofluorescence. It was initially quantified and after 8 weeks of treatment with S, RA and
      N. RESULTS: Relative expression of DNA methyl transferases were significantly elevated
      compared with unaffected skin in all subjects indicating hypermethylation of DNA.
      Hypermethylation decreased by S (7 vs 3 times relative expression, p&lt;0.05), RA (7 vs 2 times
      relative expression p&lt;0.05), and N (7 vs 1 relative expression p&lt;0.01) correlated with
      clinical improvement, this was also supported by immunohistochemistry and immunofluorescence.
      CONCLUSIONS: The investigators found hypermethylation of DNA in melasma lesions.
      Environmental factors such as sun radiation may induce DNA hypermethylation triggering
      hyperpigmentation trough the activation of pathways regulated by epigenetic modifications.
      Thus, decreasing methylation by sunscreen protection and the genetic transcription
      modification through N and RA, may allow their clinical improvement regardless its
      depigmenting effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">January 1, 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double bind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>improve in the level of DNA methylated</measure>
    <time_frame>8 weeks</time_frame>
    <description>Decrease in levels of expression of DNA methyl transferases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improve in the clinical severity of melasma</measure>
    <time_frame>8 weeks</time_frame>
    <description>decrease in the MASI score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Macules of melasma without any treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Niacinamide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macules of melasma treated with topical Niacinamide cream 4% for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinoic acid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macules of melasma treated with topical retinoic acid 0.05% for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunscreen group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Macules of melasma treated with sunscreen cream with a 50 sun protection factor for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retinoic acid</intervention_name>
    <description>topical administration in melasma lesions</description>
    <arm_group_label>Retinoic acid group</arm_group_label>
    <other_name>Niacinamide</other_name>
    <other_name>Sunscreen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>colorimetry measurement</intervention_name>
    <description>Measurement of erythema and luminosity through a colorimeter</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Niacinamide group</arm_group_label>
    <arm_group_label>Retinoic acid group</arm_group_label>
    <arm_group_label>Sunscreen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunscreen</intervention_name>
    <description>topical administration in melasma lesions</description>
    <arm_group_label>Sunscreen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacinamide</intervention_name>
    <description>topical administration in melasma lesions</description>
    <arm_group_label>Niacinamide group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical diagnosis of malar melasma by a specialist. No previous treatment at the beginning
        of the study.

        Exclusion Criteria:

        Use of medications associated with the development of melasma. Pregnant or lactating
        patients. Presence of concomitant diseases associated with the development of melasma. or
        other facial hyperpigmentations (thyroid, liver).

        Have received treatment in the last 2 months. Regular use of sunscreen.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 6, 2018</last_update_submitted>
  <last_update_submitted_qc>January 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de San Luis Potosí</investigator_affiliation>
    <investigator_full_name>Juan Pablo Castanedo-Cazares</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Epigenetics, Malar melasma,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Sunscreening Agents</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

